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Abstract
NRF2 is a transcription factor that mediates stress responses. Oncogenic mutations in NRF2
localize to one of its two binding interfaces with KEAP1, an E3 ubiquitin ligase that promotes
proteasome-dependent degradation of NRF2. Somatic mutations in KEAP1 occur commonly in
human cancer, where KEAP1 may function as a tumor suppressor. These mutations distribute
throughout the KEAP1 protein but little is known about their functional impact. In this study, we
characterized 18 KEAP1 mutations defined in a lung squamous cell carcinoma tumor set. Four
mutations behaved as wild-type KEAP1, thus are likely passenger events. R554Q, W544C,
N469fs, P318fs, and G333C mutations attenuated binding and suppression of NRF2 activity. The
remaining mutations exhibited hypomorphic suppression of NRF2, binding both NRF2 and CUL3.
Proteomic analysis revealed that the R320Q, R470C, G423V, D422N, G186R, S243C, and V155F
mutations augmented the binding of KEAP1 and NRF2. Intriguingly, these 'super-binder' mutants
exhibited reduced degradation of NRF2. Cell-based and in vitro biochemical analyses
demonstrated that despite its inability to suppress NRF2 activity, the R320Q 'superbinder' mutant
maintained the ability to ubiquitinate NRF2. These data strengthen the genetic interactions
between KEAP1 and NRF2 in cancer and provide new insight into KEAP1 mechanics.
Introduction
In contrast to the mutational clustering seen in oncogenes, where a few residues are
frequently affected, mutations in tumor suppressor proteins typically lack focal enrichment.
This creates uncertainty as to the impact of specific mutations on protein function; mutations
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may be phenotypically silent ‘passenger’ events, they may result in a spectrum of
hypomorphs, or produce a functionally dead protein. Catalogued associations between
specific cancer genotypes and protein function will instruct many principles of cancer
biology and oncology, including patient stratification for targeted therapy.
The Cancer Genome Atlas (TCGA) recently reported the characterization of 178 squamous
cell lung carcinomas (SQCC), revealing at least 10 recurrently mutated genes. Among these
were activating mutations in the NFE2L2 (NRF2) oncogene and presumed loss-of-function
mutations within the KEAP1 tumor suppressor gene, at 15% and 12% of tumors,
respectively (1). KEAP1 functions as a substrate recognition module within the CUL3-based
E3 ubiquitin ligase, which targets the NRF2 transcription factor for proteosomal degradation
(2). Regardless of tissue origin, nearly all somatic mutations within NRF2 fall to either the
ETGE or the DLG motif, two regulatory short amino acid sequences within NRF2 that
contact KEAP1 (3). As such, these mutations liberate NRF2 from KEAP1-mediated
ubiquitination. Comparatively, a survey of cancer genomic data revealed 213 somatic
mutations dispersed across the full length of the KEAP1 protein, a pattern consistent with
the mutational spread often seen in tumor suppressor genes. Like many discoveries from
genomic sequencing efforts, the functional consequences of these KEAP1 mutations are
largely not known.
The lung SQCC analysis revealed that as expected, KEAP1 mutations and NRF2 mutations
do not co-occur in the same tumor, and that tumors with KEAP1 or NRF2 mutations express
relatively high levels of NRF2-target mRNAs (1, 4). NRF2 target genes include a host of
stress response genes, such as heme oxygenase 1 (HMOX1), NADPH dehydrogenase
quinone 1 (NQO1), and genes involved in glutathione synthesis (5). The expression of these
genes strengthens the cellular defense system to neutralize reactive oxygen species (ROS),
clear xenobiotic agents, and reprogram protein degradation machinery to restore
homeostasis. Recent studies also establish a role for NRF2 in modulating anabolic pathways
to suit the metabolic demands of cancer cell growth, effectively yielding an increase in
cancer cell proliferation (6). Although comprehensive data are not complete, several studies
have reported that NRF2 activity correlates with poor prognosis and chemotherapeutic
resistance (7–10).
The now established importance of KEAP1-NRF2 in promoting cancer cell growth and
survival underscores the need to elucidate how cancer evolution leads to pathway activation.
Several mechanisms are easily recognized from cancer genomic studies: activating
mutations in NRF2 free it from KEAP1 association (11), copy number amplifications of the
NRF2 genomic locus increase protein expression, and KEAP1 promoter hypermethylation
decreases its mRNA and protein expression (12, 13). What remains uncertain is which
somatic mutations within KEAP1 affect its function, to what degree do they impact function,
and mechanistically how its function is compromised. Recent efforts from several groups
have identified correlations between cancer genotype and phenotype, and these findings may
have a significant impact on clinical interventions (14–18). With these concepts in mind, we
functionally tested and biochemically characterized KEAP1 mutations found within lung
SQCC. Our data connects cancer-derived KEAP1 genotypes with NRF2 phenotype.
Unexpectedly, we found that many KEAP1 mutant proteins bind and ubiquitinate NRF2, but
do not promote its proteosomal degradation or suppress its transcriptional activity.
Materials and Methods
Tissue culture, transfections, and siRNAs
HEK293T, A549, and H2228 cells were obtained from the American Tissue and Culture
Collection, which authenticates cells line using short tandem repeat analysis. Cell lines were
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not passaged for more than 6 months after resuscitation. The Keap1−/− MEFs were kindly
provided by Thomas Kensler and Nobunao Wakabayshi. HEK293T cells were grown in
Dulbecco's Modified Eagle's Medium, supplemented with 10% FBS and 1% GlutaMAX
(Life Technologies) in a 37°C humidified incubator with 5% CO2. Keap1−/− mouse embryo
fibroblasts (MEF) were cultured in IMDM supplemented with 10% FBS. A549 and H2228
cells were grown in RPMI supplemented with 10% FBS. Expression constructs were
transfected in HEK293T cells with Lipofectamine 2000 (Life Technologies). A549 cells and
Keap1−/− MEFs were transfected with Fugene HD (Roche). Transfection of siRNA was
done with Lipofectamine RNAiMAX (Life Technologies). siRNA sequences for CUL3 are
as follows: (A) 5’-GGU CUC CUG AAU ACC UCU CAU UAU U, (B) 5’-GAA UGU
GGA UGU CAG UUC ACG UCA A, (C) 5’-GGA UCG CAA AGU AUA CAC AUA UGU
A.
Antibodies and buffers employed for Western blot analysis: anti-FLAG M2 monoclonal
(Sigma), anti-HA monoclonal (Roche), anti-βactin polyclonal (Sigma, A2066), anti-βtubulin
monoclonal (Sigma, T7816), anti-KEAP1 polyclonal (ProteinTech, Chicago IL), anti-GFP
(abcam, ab290), anti-NRF2 H300 polyclonal (Santa Cruz, Santa Cruz CA), anti-SLK
(Bethyl, A300-499A), anti-DPP3 (abcam, ab97437), anti-MCM3 (Bethyl, A300-123A),
anti-WTX (19), anti-IKKβ (Cell Signaling, 2678), anti-p62/SQSTM (Santa Cruz, sc25575),
HMOX1 (abcam, ab13248), anti-CUL3 (Cell Signaling, 2759), anti-MEK1/2 (Cell
Signaling, 8727), anti-histone 3 (Cell Signaling, 4499), anti-GST (Cell Signaling, 2622), and
anti-VSV polyclonal (Bethyl, A190-131A). 0.1% NP-40 lysis buffer: 10% glycerol, 50mM
HEPES, 150 mM NaCl, 2mM EDTA, 0.1% NP-40; RIPA buffer: 0.1% NP-40, 0.1% SDS,
10% glycerol, 25mM Tris HCl, 0.25% sodium deoxycholate, 150mM NaCl, 2mM EDTA.
Immunopurification, cell fractionation, and Western blotting
For FLAG immunopurification, cells were lysed in 0.1% NP-40 lysis buffer. Cell lysates
were cleared by centrifugation and incubated with FLAG resin (Sigma) before washing with
lysis buffer and eluting with NuPAGE loading buffer (Life Technologies). For
immunoprecipitation of endogenous NRF2, cells were lysed in 0.1% NP-40 lysis buffer.
Cell lysates were cleared by centrifugation, and pre-cleared for 1 hour with Protein A/G
resin (Pierce). Lysates were then incubated with NRF2 H-300 antibody (Santa Cruz)
overnight at 4 degree Celsius, and then incubated for 1 hour with Protein A/G resin before
eluting with NuPAGE loading buffer. For siRNA, HEK293T cells were transiently
transfected and lysed in RIPA buffer 60 hours post transfection. Cell fractionation was
performed using the NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (Thermo
Scientific).
Plasmids, expression vectors, and site-directed mutagenesis
Expression constructs for the KEAP1 mutants were generated by PCR-based mutagenesis
and sequence verified before use; primer sequences for the mutagenesis are shown in Table
S3. The TCGA tumor sample codes for each mutation are also shown in Table S3. The
reporter construct for human hNQO1-ARE-luciferase was a kind gift from Jeffrey Johnson.
ARE luciferase quantification
Cells were transfected with expression constructs, FLAG-KEAP1, FLAG-NRF2, hNQO1-
ARE luciferase, and a control plasmid containing Renilla luciferase driven by a constitutive
cytomegalovirus (CMV) promoter. Approximately 24 hours post-transfection, NRF2-
mediated transcription was measured as the ratio of Firefly to Renilla luciferase activity
(Promega Dual-Luciferase Reporter Assay System).
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Ubiquitination of NRF2 under denaturing conditions was performed in HEK293T cells
stably expressing FLAG-KEAP1 wild-type or R320Q, VSV-UB1, FLAG-NRF2, and
Venus-NPM1. Cells were first lysed in denaturing buffer (25mM Tris, 150mM NaCl, 1%
SDS, 1mM EDTA), then diluted with 0.1% NP-40 buffer, followed by immunoprecipitation
of NRF2. For in vitro ubiquitination studies, GST-tagged wild-type Keap1 and the R320
mutant were over-expressed in Hi5 insect cells and purified using a glutathione affinity
column. After removal of the GST tag, the proteins were further purified by ion exchange
chromatography. For the in vitro ubiquitination assay, wild-type KEAP1 or the R320Q
mutant was mixed with recombinant human E1, UbcH5, CUL3-RBX1, ubiquitin and GST-
tagged NRF2 NEH2 domain (GST-NRF2-Neh2) in buffer containing 40 mM Tris-HCl pH
8.0, 5 mM MgCl2, 2 mM DTT and 4 mM ATP. Ubiquitination was carried out at 37 °C and
the products were analyzed by Western blot with anti-GST antibody.
Immunonstaining
HEK293T cells were cotransfected with the indicated plasmids and plated on 10 µg/mL
fibronectin-coated coverslips. Cells were fixed in 4% paraformaldehyde in cytoskeletal
buffer for 15 minutes, and coverslips were mounted to slides using the Prolong Gold
antifade reagent (Molecular Probes). Images were acquired using a Zeiss LSM5 Pascal
Confocal Laser Scanning Microscope equipped with ×63/1.42 Oil PlanApo objective lenses.
Affinity purification and mass spectrometry
For streptavidin and FLAG affinity purification, cells were lysed in 0.1% NP-40 lysis buffer.
Cell lysates were incubated with streptavidin or FLAG resin and washed 5 times with lysis
buffer. The precipitated proteins were trypsinized directly on beads using the FASP Protein
Digestion Kit (Protein Discovery).
Protein identification, filtering, and bioinformatics
All raw data were converted to mzXML format before a search of the resultant spectra using
SorcererTM-SEQUEST® (build 4.0.4, Sage N Research) and the Transproteomic Pipeline
(TPP v4.3.1). Data were searched against the human UniProtKB/Swiss-Prot sequence
database (Release 2011_08) supplemented with common contaminants, i.e. porcine (Swiss-
Prot P00761) and bovine (P00760) trypsin, and further concatenated with its reversed copy
as a decoy (40,494 total sequences). Search parameters used were a precursor mass between
400 and 4500 amu, up to 2 missed cleavages, precursor-ion tolerance of 3 amu, accurate
mass binning within PeptideProphet, semi-tryptic digestion, a static carbamidomethyl
cysteine modification, variable methionine oxidation, and variable phosphorylation of
serines, threonines, and tyrosines. False discovery rates (FDR) were determined by
ProteinProphet and minimum protein probability cutoffs resulting in a 1% FDR were
selected individually for each experiment. PeptideProphet/ProteinProphet results for each
APMS experiment were stored in a local Prohits database. To determine an interacting
protein's abundance relative to WT, prey spectral counts were bait normalized by dividing
by the bait spectral count, followed by calculating the number of standard deviations from
WT (similar to a Z-score), where the standard deviation was computed for each prey
individually. Unfiltered data and spectral count normalizations are provided as
Supplementary Table S2.
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Connecting cancer-derived KEAP1 mutations with NRF2 activity
A search of the literature and public domain revealed 213 somatic mutations in KEAP1,
observed across 17 cancer types and multiple cell lines (Table S1). Mapping these mutations
onto the KEAP1 primary amino acid sequence revealed a mostly uniform distribution of
affected residues (Fig. 1A). The distribution of mutations specifically found in squamous
cell lung carcinoma further reiterated the lack of a ‘mutation cluster region’ (Fig. 1A, blue
ovals). Of the 18 mutations found in lung SQCC, only two mutations resulted in a truncated
protein product (N469fs and P318fs). The remaining 16 missense mutations included the
addition of three new cysteine residues (G333C, W544C, and S243C), which might alter
KEAP1 reactivity to electrophilic agents. One mutation, V155F occurred in two separate
tumors, and interestingly, none of the mutations in KEAP1 were in residues that directly
interface with NRF2 (20). Given the importance of KEAP1-NRF2 signaling in cancer and
our inability to predict the functional consequences of KEAP1 mutation, we cloned and
comparatively evaluated each of the 18 lung SQCC mutations.
To test whether cancer-derived mutations in KEAP1 affect NRF2-driven transcription, we
used an engineered reporter system, wherein the luciferase gene is expressed in a NRF2-
dependent manner. Ectopic expression of wild-type KEAP1 suppressed NRF2-dependent
luciferase expression in HEK293T cells (Fig. 1B). By comparison, the KEAP1 mutants
displayed variable suppression of NRF2-driven transcription. Specifically, L231V, S224Y,
P318L and R71L suppressed NRF2 as well as wild-type KEAP1; these genotypes represent
possible passenger mutations within KEAP1. By contrast, N469fs, P318fs, and G333C
exhibited a near-null phenotype. Most surprisingly, of the 18 mutants examined, 11 retained
partial ability to suppress NRF2-driven transcription. To further validate these data, we
tested the panel in the lung adenocarcinoma cell line A549, which express mutant and
inactive KEAP1G333C, and in Keap1 knockout mouse embryo fibroblasts (MEFs). In all
three cell lines tested, which vary in KEAP1 genotype, we observed a consistent pattern of
KEAP1-mediated NRF2 suppression (Fig. 1C and D).
At its core, this work sought to isolate and functionally annotate specific KEAP1 genotypes
so that clinical correlations and predictions might be drawn from genome sequence data
alone. As such, we tested whether the relative activities of each KEAP1 mutant correlated
with the expression of 15 NRF2 target genes within the lung SQCC TCGA cohort (1, 4).
Comparing luciferase activity (Fig. 1B–D) to the NRF2 transcriptional gene signature, we
found that mutants that suppress like wild-type KEAP1 associate with decreased NRF2
activity, whereas mutants unable to completely suppress NRF2 correlate with increased
NRF2 target gene expression (p=0.049; two-sided Wilcoxon Rank Sum Test) (Fig. S1A).
Any attempt to further segregate mutations based on luciferase activity did not show a
statistically significant correlation in the patient data.
Biochemical characterization of the KEAP1 mutants
Next, we sought molecular insight into how specific mutations differentially impacted
KEAP1 function. First, we determined whether the mutants expressed at levels similar to
wild-type KEAP1, as non-synonymous mutations often impair protein folding to decrease
protein stability. Transient expression from plasmid DNA indicates that the majority of
KEAP1 mutants expressed at levels similar to wild-type protein (Fig. 2A and S1B). Further
study is required to determine if the reduced expression of mutants R554Q, W544C, N469fs,
P318fs, G480W, and G333C is due to altered protein or mRNA stability. To extend these
data, the subcellular localization of KEAP1 and each KEAP1 mutant was evaluated in
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HEK293T cells; all mutants exhibited a localization pattern indistinguishable from wild-type
KEAP1 (Fig. S1C).
KEAP1 functions as a critical sensor of oxidative stress, wherein multiple cysteine residues
act as biosensors for ROS and xenobiotic molecules (11, 21, 22). In cells, KEAP1 is thought
to exist as a homodimer, creating a 2:1 stoichiometry with the NRF2 substrate. Following
cysteine modification, either by reactive oxygen species or electrophilic agents like tert-
butylhydroquinone (tBHQ), a conformational change within the KEAP1 homodimer creates
an SDS-resistant form which is readily visualized under denaturing electrophoresis (23, 24).
When treated with the pathway agonist, all 18 mutants formed an SDS-resistant dimer,
suggesting that the mutations do not impair dimerization (Fig. 2A). To more rigorously test
this, FLAG-tagged KEAP1 mutants were transfected into HEK293T cells stably expressing
wild-type hemagglutinin epitope (HA) tagged KEAP1. FLAG immunopurification of the
mutant protein, followed by Western blot for the HA-tagged wild-type protein was
performed to evaluate KEAP1 dimerization (Fig. 2B). Each KEAP1 mutant protein retained
the ability to dimerize with wild-type KEAP1.
The most likely molecular explanation for how KEAP1 mutations compromise its ability to
suppress NRF2 is that the mutations impact either the KEAP1-NRF2 association or the
KEAP1-CUL3 association. We evaluated whether the KEAP1 mutants maintain their ability
to interact with endogenous CUL3 (Fig. S2A). Immunoprecipitation and Western blot
analysis revealed that all of the KEAP1 mutants interact with CUL3 (Fig. 2C). Further
analysis is needed to determine if the subtle differences in CUL3 binding reflect differential
affinities or expression variability (Fig 2C, compare lanes 15, 16, 19). Next we determined if
the KEAP1-NRF2 association was maintained among the mutants. Western blot analysis of
immunopurified KEAP1 and mutant KEAP1 protein complexes showed that the R554Q,
W544C, N469fs, P318fs, and G333C mutants failed to bind NRF2 (Fig. 3A and S2B and
S2C). Surprisingly, however, the remaining 13 KEAP1 mutants retained NRF2 binding.
Together, these data suggest that with the exception of R554Q, W544C, N469fs, P318fs,
and G333C, SQCC-derived KEAP1 mutants maintain their ability to bind both NRF2 and
CUL3.
Mass spectrometry-based proteomic analysis of KEAP1 revealed 42 high confidence
associated proteins (4). To gather a global perspective of how the mutations affect KEAP1
protein interactions, we performed two experiments. First, we tested the association of 7
high confidence interacting proteins by immunoprecipitation and Western blot analysis. The
data show a distinct pattern among the KEAP1 mutants; those that do not bind NRF2 fail to
bind several of the known interactors, including SLK, AMER1 (WTX), MCM3, DPP3, and
IKBKB (IKKβ) (Fig. 3A and S2C). Interestingly, all of these proteins contain an ETGE
motif (4). Two mutations, G480W and S224Y, show decreased binding to SLK, MCM3, and
DPP3 as compared to NRF2 (Fig. 3A, lanes 8, 15). Second, we employed affinity
purification and shotgun mass spectrometry to define and compare the protein interaction
network for wild-type KEAP1 and the following mutants: R554Q, R320Q, R470C, G480W,
G423V, D422N, G186R, S243C, and V155F (Fig. 3B and Table S2). The unbiased
proteomic screens confirm the Western blot results and further expand the pattern of altered
protein interactions.
A class of KEAP1 mutants with increased NRF2 binding
We were particularly intrigued with a subset of mutants that consistently bound more NRF2
than wild-type KEAP1 (Fig. 3A, lanes 3, 5, 6, 9, 14, 16, 19, and Fig. S2C). We collectively
refer to these mutants as the ‘superbinders’, although relative protein affinity is not meant to
be inferred. The superbinder mutants include R320Q, R470C, G423V, D422N, G186R,
S243C and V155F. Increased abundance of NRF2 within each superbinder protein complex
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was confirmed by immunoprecipitation and quantitative Western blot analysis (Fig. S3A
and S3B). Additionally, label-free mass spectrometry comparing wild-type KEAP1 and two
superbinder mutants (R320Q and R470C) showed an increased abundance of NRF2 as
compared to wild-type KEAP1; based on spectral counts, R320Q and R470C bound 3.3 and
3.2 fold more NRF2 than wild-type KEAP1, respectively (Fig. 3B and Table S2). For
comparative purposes, we performed quantitative proteomic analysis on two non-
superbinder mutant proteins: R554Q, which cannot bind NRF2 and G480W, which binds
NRF2 similarly to wild-type (Fig. 3B).
Despite an increased level of associated NRF2, the superbinder mutants were unable to
suppress NRF2-mediated transcription of an artificial reporter gene (Fig. 1B–D). To confirm
this using endogenous metrics of NRF2 activity, HEK293T cells, H2228 cells or A549 cells
were transiently transfected with wild-type KEAP1 or the superbinder mutants before
Western blot analysis of NRF2 and the NRF2 target gene HMOX1. Transient expression of
each superbinder strongly increased the levels of NRF2 and HMOX1 in the H2228 and
A549 cell lines (Fig. 4A and B). Subcellular fractionation of the HEK293T cells further
revealed that KEAP1 superbinder expression increased the levels of NRF2 within the
nuclear compartment (Fig. 4C and S3C).
KEAP1 ‘superbinder’ mutants facilitate NRF2 ubiquitination but not degradation
Our functional and biochemical examination revealed 7 KEAP1 mutations that show
significantly impaired ability to suppress NRF2, but yet unexpectedly bind more NRF2 than
wild-type KEAP1. To gain further insight, we evaluated NRF2 protein turnover and
ubiquitination following KEAP1 superbinder expression. Using a cycloheximide pulse-
chase approach, NRF2 protein half-life was evaluated in HEK293T cells stably expressing:
1) wild-type KEAP1, 2) the R320Q superbinder, 3) R470C superbinder, 3) R554Q which
does not bind NRF2, or 5) G480W which behaves like wild-type. The expression of R320Q
or R470C dramatically stabilized the NRF2 protein as compared to no exogenous KEAP1,
wild-type KEAP1 or G480W (Fig. S3D and Fig. 5A). The increased NRF2 stability
occurred as a result of binding R320Q or R470C, as unbound NRF2 in the flow-through
eluate showed elevated levels but dynamic turnover (Fig. 5B, compare flow-through to
KEAP1 immunopurification). Together, these data suggest that the superbinder mutations
within KEAP1 result in the stabilization of KEAP1-associated NRF2 and elevated levels of
free NRF2, although the free NRF2 is still subject to dynamic turnover.
Given the increased NRF2 association and protein stability, we hypothesized that R320Q
and other superbinder mutants impair NRF2 ubiquitination. To test this, we performed two
complementary experiments to evaluate NRF2 ubiquitination by wild-type KEAP1 or the
R320Q superbinder. First, Western blot analysis of immunoprecipitated NRF2, after
denaturation, showed robust ubiquitination by both wild-type KEAP1 and R320Q (Fig. 5C).
Second, we performed in vitro ubiquitination reactions using purified proteins (Fig. 5D).
Remarkably, both experimental approaches demonstrate that wild-type KEAP1 and R320Q
ubiquitinate NRF2.
Discussion
With some latitude, we can classify the 18 KEAP1 mutations into three classes. First, the
L231V, S224Y, P318L and R71L mutations did not impact the KEAP1-NRF2 association or
the suppression of NRF2 activity. These mutations likely represent passenger events within
KEAP1, at least with respect to NRF2. Second, and not surprisingly, the frame shift
mutations N469fs and P318fs, as well as G333C, R554Q and W544C did not bind NRF2
and did not or weakly suppressed NRF2-mediated transcription. These genotypes represent
null or near-null alleles. Third, the remaining nine mutations fell within a hypomorphic
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phenotypic range, with suppression occurring between 30–60% of the wild-type KEAP1.
Biochemically, the hypomorphic mutants displayed either reduced NRF2 binding or
surprisingly, increased binding (the superbinders).
Mutations in tumor suppressor genes often results in complete loss of protein expression or
the expression of a truncated protein product (25). It is therefore intriguing to consider why
KEAP1 is rarely lost through genomic deletion, despite being located between the
SMARCA4 and STK11 tumor suppressor genes on 19p (cBioPortal). A number of loosely
connected observations raise the possibility that KEAP1 may exert cancer-relevant functions
that extend beyond regulation of oxidative stress and NRF2. First, we found that many
KEAP1 mutations result in a hypomorphic phenotype, rather than a genetic null. Second, in
general, these hypomorphic mutations do not affect the global KEAP1 protein interaction
network, suggesting that some KEAP1 protein interactions are retained in the absence of
NRF2 suppression (Fig. 3B and Table S2). Indeed, KEAP1 associated proteins regulate a
number of disparate cellular processes, including cell cycle, migration, and apoptosis (4, 26–
34). Third, while the presence and importance of NRF2-independent KEAP1 functions
remain unknown, we and others have established that several KEAP1 interacting proteins
drive NRF2 activation via a competitive binding mechanism (4, 19, 35–37). Previously, we
found that hypomorphic KEAP1 mutants can be further inactivated by the ETGE-containing
competitive binding protein, DPP3(4). Coupled with the observed over-expression of DPP3
in lung squamous cell carcinoma, these observations suggest that from the perspective of
cancer cell fitness, the presence of a hypomorphic KEAP1 mutation may be more valuable
than a null mutant.
The most surprising and perhaps exciting discovery we observed was the identification of
the ‘superbinders’—those that do not suppress NRF2-mediated transcription, exhibit
enhanced binding to NRF2, and facilitate NRF2 ubiquitination. Three points of discussion
are appropriate. First, by what mechanism could the ‘superbinder’ mutations affect NRF2
stability? Several possibilities exist, including an increased affinity between KEAP1 and
NRF2 as a means to suppress substrate turn-over. Analogously, the expression of a
superbinder variant SH2 domain antagonizes epidermal growth factor signaling via
competitive inhibition (38). That said, although studies are ongoing, the lack of a focal
enrichment within the tertiary structure casts some doubt on this possibility (Fig. 5E). Cullin
ring E3 ubiquitin ligases cycle through an active and inactive state, and this neddylation-
dependent transitioning is required for substrate turnover. A second possibility is that the
superbinder mutations simply slow the rate of CUL3 neddylation. Finally, proteasome-
mediated substrate degradation requires several steps, including recognition, unfolding,
translocation, and deubiquitination prior to proteolysis (39). The striking observation that the
enhanced NRF2 binding class of KEAP1 mutants ubiquitinates NRF2 suggests that the
mutations functionally hinder one of the steps prior to proteolysis, but after ubiquitination.
Here, immediate questions include whether the superbinder mutations affect the ubiquitin
chain linkage on NRF2 or whether they perturb the interaction of KEAP1 with the
proteasome. All three of these putative mechanisms to describe the superbinder phenotype
would inactivate KEAP1 and stabilize NRF2 in a manner consistent with the widely
accepted “saturation model” (22). Importantly, as the KEAP1 mutants described in this study
exhibit hypomorphic phenotypes, the superbinders could represent a novel mechanism
cancer cells employ to enhance cellular fitness without compromising all cellular functions
of multifunctional proteins.
Second, it is now widely accepted that elevated levels of NRF2 are associated with enhanced
cell viability in several tumor types (7, 10, 40–42). Although we show that ‘superbinder’
mutations result in NRF2 transcriptional activation, further studies are required to determine
whether this KEAP1 mutant class is capable of enhancing cancer cell fitness in vivo, and
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whether that depends upon prolonged activation of NRF2. Additionally, given emerging
evidence identifying other putative KEAP1 substrates in cancer-relevant pathways, such as
IKKβ within NF-κB signaling (5, 43), investigating how—if at all—superbinder mutations
impact these proteins could also have clinical significance. Looking at the full set of KEAP1
mutant tumors and the expression of 15 NRF2 target genes, a marginal but statistically
significant difference was observed between phenotypically ‘silent’ KEAP1 mutations and
mutations which suppress KEAP1-driven NRF2 degradation (Fig. S1A). Our attempts to
more precisely correlate KEAP1 genotype with the cell-based phenotypic scoring failed to
reach statistical significance. This is not surprising given the multitude of signaling and
metabolic inputs that control KEAP1.
Third, from a structural perspective, we noted weak correlation between the tertiary position
of a mutation and whether the mutation produced a KEAP1 superbinder (Fig. 5E). Although
speculative, the superbinder mutations appear to be localized at positions that might orient
the relative position of IVR and KELCH domains; experiments testing this model are
ongoing. Intriguingly, of the 181 missense mutations reported in KEAP1, 6 directly target
the R320 superbinder residue, making it the most commonly affected amino acid in KEAP1
(Fig. 1A). Beyond the superbinder mutations, mapping all SQCC 19 mutations onto the
KEAP1 structure failed to reveal a discernible pattern. Likewise, side-chain biochemistry for
the mutations varies widely, including those within the superbinder class. Cysteine reactivity
depends upon the local chemical microenvironment, which is largely dictated by the
surrounding amino acids in a protein tertiary structure. Hence, for a cysteine-dependent
biosensor like KEAP1, oncogenesis may partially suppress KEAP1 activity by selecting for
mutations which add cysteines (S243C, G333C, R470C) or which reduce the relative pKa of
existing cysteines, making them more sensitive to electrophilic attack (44). Clearly, spatial
constraints preclude the random addition of cysteines as a means to increase the reactivity of
KEAP1 to oxidative stress. New cancer-derived cysteines of functional importance would
occupy specific localizations within the folded protein. By extension of this idea, cancer-
derived mutations that create ‘hyperactive’ cysteines within KEAP1 would be expected to
produce a hypomorphic phenotype, as we have observed. Further study is needed to support
these ideas, perhaps through the functional and biochemical characterization of the other 213
cancer-derived mutations in KEAP1. To this end, medium-throughput functional analysis is
facilitated by Gateway-based cloning, outsourced mutagenesis and a strong pathway-
specific transcriptional reporter. The resulting data may better enable predictions of
genotype-phenotype relationships. However, based on the KEAP1 data presented here, it is
not yet possible to derive functional conclusions from the location of a mutation or the type
of residue substitution.
In summary, we describe the functional and biochemical characteristics of 18 mutations in
the E3 ligase adaptor protein KEAP1, which were found in patient-derived lung cancers. We
show that while most of these mutations maintain similar protein interactions to wild-type
KEAP1, all but four exhibit hypomorphic or null activity with respect to suppression of
NRF2-mediated transcription. Intriguingly, a subset of these mutations exhibit enhanced
binding to NRF2 despite an inability to suppress NRF2 activity. Functional analysis of one
of these mutants, R320Q, revealed that these mutants are still able to ubiquitinate NRF2, but
appear to be unable to facilitate its degradation. Further studies are required to elucidate the
mechanism of this class of KEAP1 mutations, including how they interact with the
proteasome, as well as whether these mutants enhance viability of cancer cells via prolonged
activation of NRF2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutations in KEAP1 positively correlate with increased NRF2 activity
A, Probability density function of KEAP1 mutations were approximated using kernel
density estimation. Lung SQCC mutations examined in this study are annotated above; all
mutations from the public domain are shown below and in Table S1. B–D, HEK293T cells
(B), Keap1 knockout mouse embryo fibroblasts (C), and A549 cells (D) were transiently
transfected with the indicated plasmids along with constitutively expressed Renilla
luciferase, and the NQO1 promoter driving Firefly luciferase. Cells were lysed and Firefly
luciferase values were normalized to the luciferase activity of the Renilla control. Error bars
represent SD from the mean over three biological replicates (NTR, N-terminal region; BTB,
tramtrack and bric-a-brac; IVR, intervening region; CTR, C-terminal region).
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Figure 2. SQCC KEAP1 mutants retain the ability to dimerize and interact with the CUL3 E3
ubiquitin ligase
A, HEK293T cells were transiently transfected with the indicated KEAP1 mutant plasmids,
and treated with 50µM tert-butylhydroquinone (tBHQ) for one hour. Cells were lysed in
RIPA buffer and expression of FLAG tagged mutants was analyzed by Western blot for the
indicated proteins. The vertical dotted line depicts the digital removal of a KEAP1 mutant
recently found not to exist. The correct mutation, P318fs, is shown in Fig.S2. B, HEK239T
cells stably expressing WT HA-KEAP1 were transiently transfected with the indicated
FLAG-tagged KEAP1 mutants. Cells were lysed in 0.1% NP-40 buffer and
immunopurification (IP) of the FLAG-tagged protein complexes were analyzed by Western
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blot for the indicated proteins (HA, Hemagglutinin). C, FLAG-tagged protein complexes
were immunopurified from HEK293T cells transiently expressing the indicated KEAP1
mutants and analyzed by Western blot for the indicated proteins (NS, non-specific).
Hast et al. Page 15













Figure 3. KEAP1 mutant proteins exhibit differential binding to interacting proteins
A, HEK293T cells expressing the indicated KEAP1 mutants were treated with 10 µM
MG132 for one hour, followed by FLAG immunopurification. Protein complexes of the
FLAG-tagged mutants were analyzed by Western blot for the indicated proteins. Red lines
indicate KEAP1 mutants that were analyzed by mass spectrometry as indicated in (B). B,
Affinity purification and mass spectrometry (APMS) experiments were performed via
affinity purification of streptavidin-tagged KEAP1 mutants from stable HEK293T cells
followed by MS analysis of the bound proteins. Colors represent normalized spectral counts
– semi-quantitative values that reflect protein abundance – from the APMS experiments.
Proteins displayed are previously identified high-confidence KEAP1 interactors.
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Figure 4. Expression of KEAP1 superbinder mutants enhances nuclear localization of NRF2
A, H2228 cells were co-transfected with the indicated FLAG-tagged KEAP1 mutant plasmid
or negative control Venus-NPM1, and NRF2 plasmid. Cells were lysed in RIPA buffer and
analyzed by Western blot for the indicated proteins. B, A549 cells were transiently
transfected with the indicated KEAP1 mutants or Venus-NPM1, and protein lysates were
analyzed as described in (A). C, HEK293T cells were transiently transfected with the
indicated FLAG-tagged KEAP1 mutants. Cells were fractionated into nuclear and
cytoplasmic fractions and lysates were analyzed by Western blot for the indicated
endogenous (NRF2, MEK1/2, H3) and ectopically expressed proteins.
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Figure 5. KEAP1 superbinder mutants cannot degrade NRF2 but maintain the ability to
ubiquitinate NRF2
A, HEK293T cells stably expressing the indicated FLAG-tagged KEAP1 mutants were
transiently transfected with NRF2. Cells were treated with 50 µg/mL cycloheximide (CHX)
for the indicated time, and cell lysates were analyzed by Western blot for the specified
proteins. B, HEK293T cells stably expressing the indicated FLAG-tagged KEAP1 mutants
were treated with CHX as described in (A). FLAG immunopurification was performed to
isolate protein complexes containing the indicated KEAP1 mutants. Whole cell lysate
(INPUT), immunopurified complexes (IP:FLAG), and eluate (UNBOUND FRACTION)
were analyzed by Western blot for the indicated proteins. Values represent NRF2
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quantitation relative to FLAG-tagged KEAP1 expression. C, HEK293T cells stably
expressing either FLAG-tagged wild-type KEAP1 or the R320Q mutant were transfected as
described in (A). Cells were lysed under denaturing conditions, and then diluted to
physiological pH in 0.1% NP-40 lysis buffer. Immunopurification of NRF2 was performed,
and protein complexes were analyzed by Western blot. D, Purified KEAP1 or the R320Q
mutant was mixed with recombinant human E1, UbcH5, CUL3-RBX1, ubiquitin and GST-
tagged NRF2 NEH2 domain. Ubiquitinated NRF2 was detected by Western blot analysis. E,
The BTB and IVR domains of KEAP1 (green) were modeled by the I-TASSER server. The
BTB domain of the second copy of KEAP1 within the dimer is shown in cyan. Superbinder
residues are shown in red spheres. R320 is located in a predicted short linker connecting the
BTB-IVR domain and KELCH domain.
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